The efficacy and safety of adalimumab in ocular inflammatory disease

Abstract

Objective: To evaluate the efficacy and safety of adalimumab in the management of ocular inflammation at our institution. Methods: We performed a review of all patients with active ocular inflammation treated with adalimumab at our institution. Results: Seventy eyes of 49 patients were reviewed. The mean duration of follow-up was 19.6 months. Therapy with an average of 2.1 immunomodulatory agents had been attempted prior to adalimumab therapy. At 1-year follow-up, adalimumab was effective in achieving quiescence in 33 eyes (47%). The most common side effects were injection-site reactions, arthralgias, and nausea, occurring in two patients each. Adalimumab was discontinued due to side effects in 12 patients. Conclusion: These results suggest that adalimumab is an effective and safe therapeutic modality in ocular inflammation.